Actavis launched Montelukast tablets immediately after patents expired in Europe

Zug, Switzerland, 21-3-2013 — /europawire.eu/ — Actavis, Inc. (NYSE: ACT) has launched Montelukast tablets immediately after patent expiry in Denmark, France, Germany, Ireland, Italy, the Netherlands, Slovenia, Spain, Sweden and the UK. In Austria, Actavis started pricing and reimbursement on Day 1.

The generic equivalent of Merck’s Singulair®, Montelukast tablets are indicated for the treatment of asthma. Montelukast Actavis is available as regular tablets for ages 15 years and older and chewable tablets for children, 2-5 and 6-15 years old.

For the 12 months ending September 2012, Montelukast 10 mg tablets had branded and generic sales of approximately EUR458M in Europe, according to IMS Health data, while Montelukast chewable tablets, 4mg and 5mg, sold for about EUR153M during the same period.

Montelukast tablets are manufactured by Actavis in Malta.

About Actavis
Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland.

Actavis is the world’s third-largest generics prescription drug manufacturer. Operating as Actavis Pharma, the Company develops, manufactures and markets generic, branded generic, legacy brands and Over-the-Counter (OTC) products in more than 60 countries. The Company is ranked in the top 3 in 12 global markets, the top 5 in 16 global markets, and in the top 10 in 33 global markets. Actavis Pharma also develops and out-licenses generic pharmaceutical products outside the U.S. through its Medis third-party business, the world’s largest generic pharmaceutical out-licensing business. Medis has more than 300 customers globally, and offers a broad portfolio of more than 200 products.

Actavis Specialty Brands is the Company’s global branded specialty pharmaceutical business, which develops and markets a portfolio of approximately 40 products principally in the United States and Canada that are focused in the Urology and Women’s Health therapeutic categories. Actavis Specialty Brands is committed to developing and marketing biosimilars products in Women’s Health, Oncology and other therapeutic categories, and currently has a portfolio of 5 biosimilar products in development.
Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, with a capacity of approximately 44 billion units annually. Actavis Global Operations also includes Anda, Inc., the fourth-largest U.S. generic pharmaceutical product distributor in the United States.

For press release and other company information, visit Actavis’ Web site at www.actavis.com.

Forward-Looking Statement
Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Actavis’ current perspective of existing information as of the date of this release. It is important to note that Actavis’ goals and expectations are not predictions of actual performance. Actual results may differ materially from Actavis’ current expectations depending upon a number of factors, risks and uncertainties affecting Actavis’ business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with governmental laws, rules and regulations applicable to Actavis and its third party manufacturers’ facilities, products and/or businesses; changes in the laws and regulations affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Actavis’ periodic public filings with the Securities and Exchange Commission, including but not limited to Actavis’ Annual Report on Form 10-K for the year ended December 31, 2012 . Except as expressly required by law, Actavis disclaims any intent or obligation to update these forward-looking statements. Singulair® is a registered trademark of Merck & Co., Inc.

Media Enquiries:
Elisabet Hjaltadottir
+354 860 3959